Guasch-Ferré M, Ruiz-Canela M, Li J, et al. Plasma Acylcarnitines and Risk of Type 2 Diabetes in a Mediterranean Population at High Cardiovascular Risk. J Clin Endocrinol Metab. 2019;104(5):1508-1519. doi:10.1210/jc.2018-01000.

Gelaye B, Clish CB, Denis M, et al. Metabolomics signatures associated with an oral glucose challenge in pregnant women. Diabetes Metab. 2019;45(1):39-46. doi:10.1016/j.diabet.2018.01.004.

Nowak C, Hetty S, Salihovic S, et al. Glucose challenge metabolomics implicates medium-chain acylcarnitines in insulin resistance. Sci Rep. 2018;8(1):8691. doi:10.1038/s41598-018-26701-0.

Kalim S, Clish CB, Wenger J, et al. A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients. J Am Heart Assoc. 2013;2(6):e000542. doi:10.1161/JAHA.113.000542.